Literature DB >> 48247

Immunological escape mechanism in spontaneously metastasizing mammary tumors.

U Kim, A Baumler, C Carruthers, K Bielat.   

Abstract

Immunological and biochemical studies of spontaneously metastasizing and nonmetastasizing rat mammary carcinomas and their plasma membranes indicated that: (i) all spontaneously metastasizing tumors have little or no demonstrable glycocalyx, while all nonmetastasizing tumors have a thick glycocalyx; (ii) there is a direct relationship between the glycocalyx and immunogenicity, and an inverse relationship with the metastasizing capacity of tumor cells, properties which can be quantitated by levels of the plasma membrane marker enzyme 5'-nucleotidase (EC3.1.3.5;5'-ribonucleotide phosphohydrolase) activity; (iii) the absence of glycocalyx from the metastasizing tumor cell surface seems to result from its dissociation from plasma membranes, for solubilized cell surface antigen is readily found in the blood of metastasizing tumor bearing rats, while there was no detectable tumor cell surface antigen in the blood of the nonmetastasizing tumor hosts tested; (iv) both metastasizing and nonmetastasizing mammary tumors appear to have a common soluble cell surface antigen; (v) in addition to this common antigen, there is another membrane-bound antigen in the nonmetastasizing, immunogenic tumor cell surface which presumably is the tumor specific transplantation antigen; and (vi) this antigen is immunobiologically unique, but seems to be immunochemically related to the common soluble antigen. It is postulated that the lack of an immunogenic coat and/or the presence of solubilized tumor cell surface antigen in the blood may provide an immune escape mechanism for tumor cells by interfering with cell-mediated immune response of tumor hosts, leading to their dissemination.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 48247      PMCID: PMC432454          DOI: 10.1073/pnas.72.3.1012

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Cementing substances in metastasizing and non-metastasizing transplantable tumours in mice.

Authors:  G GASIC; F LOEBEL; O BADINEZ
Journal:  Nature       Date:  1960-03-19       Impact factor: 49.962

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Purification and properties of 5-nucleotidase.

Authors:  L A HEPPEL; R J HILMORE
Journal:  J Biol Chem       Date:  1951-02       Impact factor: 5.157

4.  Phosphatases of liver. I. Glucose-6-phosphatase.

Authors:  M A SWANSON
Journal:  J Biol Chem       Date:  1950-06       Impact factor: 5.157

5.  Changes in the affinity of phosphotungstic acid and positively charged colloidal particles for the surfaces of malignant human transitional epithelium of the urinary bladder.

Authors:  G B Dermer; W H Kern
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

6.  Cellular and humoral immunity to rat hepatoma-specific antigens correlated with tumour status.

Authors:  R W Baldwin; M J Embleton; R A Robins
Journal:  Int J Cancer       Date:  1973-01-15       Impact factor: 7.396

7.  Tumor-associated specificity of serum-mediated inhibition of lymphocyte stimulation by autochthonous human tumors.

Authors:  F Vánky; J Stjernswärd; G Klein; L Steiner; L Lindberg
Journal:  J Natl Cancer Inst       Date:  1973-07       Impact factor: 13.506

8.  Ruthenium red and violet. I. Chemistry, purification, methods of use for electron microscopy and mechanism of action.

Authors:  J H Luft
Journal:  Anat Rec       Date:  1971-11

9.  Ruthenium red and violet. II. Fine structural localization in animal tissues.

Authors:  J H Luft
Journal:  Anat Rec       Date:  1971-11

10.  Mouse histocompatibility isoantigens derived from normal and from tumour cells.

Authors:  D A Davies
Journal:  Immunology       Date:  1966-08       Impact factor: 7.397

View more
  28 in total

Review 1.  Lymphatic invasion and metastasis.

Authors:  C van de Velde; I Carr
Journal:  Experientia       Date:  1977-07-15

2.  Interaction of tritium-labeled H2DIDS (4,4'-diisothiocyano-1,2,diphenyl ethane-2,2'disulfonic acid) with the Ehrlich mouse ascites tumor cell.

Authors:  C Levinson; R J Corcoran; E H Edwards
Journal:  J Membr Biol       Date:  1979-03-28       Impact factor: 1.843

Review 3.  Studies on rat mammary adenocarcinomas: a model for metastasis.

Authors:  I A Ramshaw; P Badenoch-Jones
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

Review 4.  Generation of phenotypic diversity and progression in metastatic tumor cells.

Authors:  G L Nicolson
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

5.  Different biological behavior of AKR lymphoma cells from primary and metastatic tumors.

Authors:  J Leibovici; Y Stark; S Kopel
Journal:  Experientia       Date:  1985-03-15

6.  Decreased tumorigenicity correlates with expression of altered cell surface carbohydrates in Lec9 CHO cells.

Authors:  J Ripka; S Shin; P Stanley
Journal:  Mol Cell Biol       Date:  1986-04       Impact factor: 4.272

7.  Purification and partial characterization of a tumour-metastasis-associated high-Mr glycoprotein from rat 13762NF mammary adenocarcinoma cells.

Authors:  P A Steck; S M North; G L Nicolson
Journal:  Biochem J       Date:  1987-03-15       Impact factor: 3.857

8.  Quantitation of human mammary epithelial antigens in cells cultured from normal and cancerous breast tissues.

Authors:  M Sasaki; J A Peterson; R L Ceriani
Journal:  In Vitro       Date:  1981-02

Review 9.  Prostacyclin and its analogues: antimetastatic effects and mechanisms of action.

Authors:  M R Schneider; D G Tang; M Schirner; K V Honn
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

10.  Autologous anticancer antigen preparation for specific immunotherapy in advanced cancer patients. A phase I clinical trial.

Authors:  C A Slanetz; D L McCollester; S Kanor
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.